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litus (T1DM and T2DM,). Prescriptions were costed at UK
£2006 prices from government sources for: insulin, oral hypo-
glycaemic agents (OHAs), glucose monitoring, sharps and deliv-
ery devices and hypoglycaemia rescue medication. RESULTS:
In T1DM, 268 and 625 patients were initiated on detemir 
and glargine respectively, contributing 80 patient years and 282
patient years of treatment. In T2DM, 334 and 977 patients were
initiated respectively, contributing 108 patient years and 384
patient years. In T1DM, the mean total annual cost of diabetes-
related prescriptions was £1518 vs. £1312 (Δ = 14%, p < 0.001)
for detemir and glargine respectively, and £1592 vs. £1113 (Δ =
30%, p < 0.001) in T2DM. The difference in spending for T1DM
and T2DM for detemir with reference to glargine was as follows:
insulin +21% and +37%; OHAs (T2DM only) −24%; glucose
monitoring −1% and 20% and rescue medication +7% and 0%.
CONCLUSIONS: Patients managed with glargine as their basal
insulin generate signiﬁcantly lower prescription costs than those
managed with detemir which translated into a less costly regimen
for both T1DM and T2DM.
PDB5
PREVENTION WITH PICOTAMIDE AND ASPIRIN IN PATIENTS
WITH TYPE 2 DIABETES MELLITUS AND PERIPHERAL
ARTERIAL DISEASE:A PHARMACOECONOMIC EVALUATION
Iannazzo S1, Pradelli L1, Eandi M2
1Advanced Research Srl,Turin, Italy, 2Università di Torino,Turin, Italy
Type 2 diabetes mellitus (DM) and peripheral arterial disease
(PAD) are two very relevant cardiovascular (CV) risk factors,
which can often be found concurrently in the same patient. The
DAVID trial, a double-blind, randomized, aspirin(ASA)-
controlled study, has demonstrated that the use of picotamide, a
thromboxane A2 synthase and receptor dual inhibitor, is associ-
ated with lesser CV morbidity and mortality in this type of
patients in comparison to ASA, considered the standard
antiplatelet agent. OBJECTIVES: To estimate clinical and eco-
nomic impacts of picotamide in the Italian health care setting.
METHODS: We developed a Markov model based on clinical
data from DAVID and national economic parameters and demo-
graphics. RESULTS: The base case scenario, which reﬂects
current prices and reimbursement policy (i.e. ASA fully paid for,
picotamide out-of-pocket for patients) yielded an incremental
cost/effectiveness ratio (ICER) of about 8500 euro/year of life
(YOL) saved, which falls below conventionally adopted willing-
ness to pay thresholds. This cost, however, is totally born by the
patient, while the savings on health care expenditures for
avoided events (and less ASA) beneﬁt the National Health
Service (NHS). These results may help the physician in explain-
ing the consequences of this choice to his/her patients, facilitat-
ing a fully-informed choice. The availability of a theoretical
model allowed to explore some alternative scenarios, that indi-
cate that the ICER can be further lowered and the economical
burden better distributed through policy changes. CONCLU-
SIONS: The pharmacoeconomic model indicated that pico-
tamide is likely to be a cost/effective option for CV mortality and
morbidity prevention in patients with concurrent type 2 DM and
PAD and that the level of adoption of this strategy will depend
on willingness to pay and policy priorities of the NHS and
patients themselves.
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METHODS: A 20-week prospective randomized controlled trial
(RCT), followed by an observational visit (OV) (26–65 weeks
later), using two SMBG methods was undertaken to compare an
integrated glucose meter and electronic logbook (IGMEL) with
conventional meters and paper logbooks (CMPL) in controlling
HbA1c levels. RESULTS: The RCT demonstrated that IGMEL
patients experienced an HbA1c reduction of 0.61% compared
with 0.40% for CMPL patients (p = 0.03). The HbA1c reduction
was coupled with a slight increase in hypoglycemia for IGMEL
(0.21 events/day) compared with CMPL (0.14 events/day), but
a slight increase in monitoring (4.0 vs. 3.5 times/day). At the OV,
those that chose to remain on IGMEL maintained an HbA1c
reduction of 0.5% while those that chose to stay on CMPL
increased HbA1c by 0.2% compared to baseline. These results
were input into a peer-reviewed, validated, economic model pro-
jecting these improvements in HbA1c and hypoglycemia rates
over a patient’s lifetime. Transition probabilities, treatment and
complication costs came from published studies. Costs and clin-
ical outcomes were both discounted at 3% annually. IGMEL was
cost-saving compared with CMPL and improved life expectancy
(0.167 and 0.536 years) and quality-adjusted life expectancy
(0.124 and 0.414 years), based on RCT and OV, respectively.
IGMEL was no longer cost saving when the regimen costs
$122/year and $198/year more than CMPL based on RCT and
OV, respectively. IGMEL remained below $50,000/LE when the
IGMEL regimen was up to $597/year and $1729/year more
expensive than CMPL, based on RCT and OV, respectively.
IGMEL remained below $50,000/QALE when the IGMEL
regimen was up to $477/year and $1378/year more expensive
than CMPL, based on RCT and OV, respectively. CONCLU-
SIONS: The results from this study suggest that over a diabetes
patient’s lifetime, signiﬁcant improvements in LE and QALE will
result and provide strong evidence for economic and patient-
centered value for this integrated blood glucose meter.
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OBJECTIVES: The purpose of this study was to evaluate the rel-
ative cost effectiveness (cost utility) of insulin glargine in the UK
for the treatment of people with Type 1 diabetes mellitus (T1DM)
using pooled data from the Phase III clinical trials programme.
METHODS: This was a health economic evaluation using a sto-
chastic simulation model. Transition probabilities for progression
to diabetes-related complications were derived mainly from the
DCCT (Diabetes Control and Complications Trial). Costs were
derived from published estimates and local data. The maximum
time horizon was 40 years to ensure effective modelling of dia-
betes patients. Utility values were extracted from the Health Out-
comes Data Repository (HODaR) and published sources. Costs
were calculated from UK £2005 prices. Costs and beneﬁts were
discounted annually at 3.5%. In this case, the model reported the
experiences of 1000 subjects averaged over ten repeat simula-
